Merck, MedImmune deal space

Merck logo

Capacity issues have led to a facility relationship deal between MedImmune and Merck ($MRK). The former will provide space in its Frederick, MD, facility for bulk product manufacturing by the latter.

Under the 15-year agreement, the companies will collaborate on capacity planning, reports The Gazette. The relationship is seen as a "long-range solution dealing with capacity issues," a MedImmune spokesperson said in the article. The work has already begun.

The 385,000-square-foot Frederick facility, opened in 1999, has about 300 employees.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The companies also are evaluating Merck plants for use by AstraZeneca's ($AZN) MedImmune unit, the article notes.


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.